Anti-Rheumatic Drugs - Southern Africa

Southern Africa

The Anti-Rheumatic Drugs market in Southern Africa is expected to witness a significant growth in revenue.
By 2024, the projected revenue is estimated to reach US$89.39m.
Furthermore, the market is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of 0.25%.
This growth trajectory is expected to result in a market volume of US$90.50m by 2029.
In terms of global comparison, it is important to note that United States will generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, the revenue generated United States is projected to be US$34,700.00m.
This highlights the dominance of the United States in this market.
The demand for anti-rheumatic drugs in Southern Africa is steadily increasing as the region grapples with a rising prevalence of rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Southern Africa has been on the rise in recent years.

Customer preferences: The market for Anti-Rheumatic Drugs in Southern Africa is primarily driven by the growing elderly population, which is more susceptible to rheumatoid arthritis and other related diseases. Additionally, the increasing awareness of these diseases and their early diagnosis has led to a surge in demand for these drugs.

Trends in the market: South Africa is the largest market for Anti-Rheumatic Drugs in the region, followed by Zimbabwe and Botswana. The market is dominated by biologic drugs, which are more effective in treating these diseases than traditional disease-modifying antirheumatic drugs (DMARDs). However, due to their high cost, DMARDs are still widely used in the region. The market is also witnessing an increasing trend towards the use of biosimilars, which are cheaper alternatives to biologic drugs.

Local special circumstances: The lack of access to healthcare facilities and the high cost of treatment are major challenges in the region. Many patients are unable to afford the high cost of biologic drugs, which are often not covered by medical aid schemes. This has led to an increasing demand for cheaper alternatives, such as DMARDs and biosimilars.

Underlying macroeconomic factors: The Southern African region is characterized by a high burden of communicable diseases, such as HIV/AIDS, malaria, and tuberculosis. The high prevalence of these diseases has put a strain on the healthcare system, which has limited resources to address non-communicable diseases such as rheumatoid arthritis. Additionally, the region is facing economic challenges, with many countries experiencing low economic growth and high levels of unemployment. This has further limited access to healthcare and the affordability of treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.